1421372-15-7 Usage
Uses
Used in Pharmaceutical Industry:
(3aR,6aR)-5-methyl-1-[(1R)-1-phenylethyl]-2,3,3a,4,6,6a-hexahydropyrrolo[3,2-c]pyrrole is used as a potential candidate for drug development due to its complex and unique structure. Its distinct stereochemistry and chirality could be leveraged to create targeted therapeutic agents with specific biological activities.
Used in Biological Research:
In the field of biological research, (3aR,6aR)-5-methyl-1-[(1R)-1-phenylethyl]-2,3,3a,4,6,6a-hexahydropyrrolo[3,2-c]pyrrole can be utilized as a tool compound to study the interactions between molecules and biological targets. Its unique structural features may provide insights into the development of new drugs with improved efficacy and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 1421372-15-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,1,3,7 and 2 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1421372-15:
(9*1)+(8*4)+(7*2)+(6*1)+(5*3)+(4*7)+(3*2)+(2*1)+(1*5)=117
117 % 10 = 7
So 1421372-15-7 is a valid CAS Registry Number.
1421372-15-7Relevant academic research and scientific papers
2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER
-
, (2013/03/26)
The present invention relates to certain 2-(2,4,5-substituted-anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
